Abstract: Dual Antiplatelet Therapy (DAPT), typically comprising aspirin and a P2Y12 receptor inhibitor, is a cornerstone pharmacological strategy for the prevention of ischemic events in both cardiovascular and cerebrovascular diseases. This review synthesizes current literature on DAPT, focusing on its application in secondary stroke prevention, percutaneous coronary intervention (PCI), and transcatheter aortic valve replacement (TAVR). While DAPT significantly reduces the risk of recurrent ischemic strokes and myocardial infarctions, its prolonged use is consistently associated with an elevated risk of major and life-threatening bleeding. Recent evidence supports a paradigm shift toward personalized medicine, advocating for short-term DAPT followed by P2Y12 inhibitor monotherapy to mitigate bleeding risks without compromising ischemic protection. Furthermore, genetic factors, such as CYP2C19 loss-of-function alleles, play a critical role in the metabolic activation and clinical efficacy of specific DAPT components like clopidogrel, guiding the structural and pharmacological selection of alternative agents like ticagrelor.
1. Introduction
Dual Antiplatelet Therapy (DAPT) is a critical antithrombotic regimen consisting of aspirin combined with a P2Y12 receptor antagonist, such as clopidogrel, ticagrelor, or prasugrel [1]. It is widely indicated for the secondary prevention of ischemic events in patients with acute coronary syndromes (ACS), those undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES), and patients experiencing minor acute noncardioembolic ischemic strokes or high-risk transient ischemic attacks (TIA) [1][2]. The fundamental clinical challenge in administering DAPT lies in balancing its potent anti-ischemic benefits against the inherent risk of hemorrhagic complications. Consequently, recent clinical trials and meta-analyses have heavily focused on optimizing the duration of DAPT and exploring de-escalation strategies, such as early aspirin withdrawal, to maximize net clinical benefit [2][3].
2. Pharmacological Activity
The pharmacological efficacy of DAPT varies significantly based on the clinical indication and the duration of therapy:
Secondary Stroke Prevention: In patients with minor acute noncardioembolic ischemic stroke or high-risk TIA, initiating DAPT within 24 hours for a duration of 21 to 30 days is more effective than single antiplatelet therapy (SAPT) in reducing stroke recurrence [1]. Landmark trials such as CHANCE and POINT demonstrated significant risk reductions in recurrent ischemic events with DAPT; however, the POINT trial, which utilized a longer 90-day DAPT duration, reported an increased rate of major hemorrhage [1].
Percutaneous Coronary Intervention (PCI): Following PCI with DES, extended-term DAPT (>12 months) is effective in reducing myocardial infarction (MI) and stent thrombosis but at the expense of increased major bleeding [2]. Conversely, short-term DAPT (1 to 3 months) followed by P2Y12 inhibitor monotherapy has been shown to significantly reduce major bleeding while maintaining noninferiority for ischemic outcomes compared to standard 12-month DAPT [2][3][9].
Transcatheter Aortic Valve Replacement (TAVR): In the context of TAVR, DAPT does not offer an ischemic advantage over SAPT. Network meta-analyses indicate that 3-month and 6-month DAPT regimens significantly increase the risk of major or life-threatening bleeding compared to SAPT with aspirin, without any significant differences in stroke prevention or all-cause mortality [7].
3. Molecular Mechanism of Action
The therapeutic effect of DAPT is achieved through the synergistic blockade of multiple platelet activation pathways. At the site of vascular injury, platelets are activated by agonists such as collagen, adenosine diphosphate (ADP), thromboxane A2 (TXA2), serotonin, and thrombin [4]. DAPT targets two primary pathways:
Cyclooxygenase-1 (COX-1) Inhibition: Aspirin (acetylsalicylic acid) acts as an irreversible inhibitor of the COX-1 enzyme. By blocking COX-1, aspirin prevents the synthesis of TXA2 from arachidonic acid, thereby diminishing TXA2-promoted platelet activation and aggregation during pathological thrombus formation [1][4].
P2Y12 Receptor Antagonism: The second component of DAPT (e.g., clopidogrel, ticagrelor, or prasugrel) targets the P2Y12 purinoceptor, a G protein-coupled receptor on the platelet membrane. By inhibiting ADP-mediated activation of the P2Y12 receptor, these agents prevent the amplification of platelet activation and subsequent cross-linking mediated by glycoprotein IIb/IIIa receptors [1][4].
4. Structure-Activity Relationship (SAR)
Because DAPT is a combination therapy, its structure-activity relationships are defined by the distinct pharmacological and metabolic profiles of its constituent drugs, particularly the P2Y12 inhibitors:
Thienopyridines (Clopidogrel): Clopidogrel is a prodrug that requires two-step hepatic biotransformation by the cytochrome P450 system, specifically the CYP2C19 enzyme, to generate its active metabolite [1]. The structural requirement for hepatic activation creates a vulnerability to genetic polymorphisms. Patients carrying CYP2C19 loss-of-function alleles (which have a prevalence of up to 58.8% in Asian populations) exhibit poor metabolism of clopidogrel, leading to reduced active metabolite levels, clopidogrel resistance, and higher rates of recurrent ischemic events [1].
Cyclopentyltriazolopyrimidines (Ticagrelor): Unlike clopidogrel, ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that does not require hepatic metabolic activation [1]. Its distinct chemical structure allows it to bypass the CYP2C19 pathway, providing a more rapid, potent, and consistent antiplatelet effect. The CHANCE-2 trial demonstrated that in patients with CYP2C19 loss-of-function alleles, ticagrelor was superior to clopidogrel in reducing the risk of new strokes [1].
5. Current Limitations
Despite its efficacy, DAPT is associated with several significant clinical limitations:
Hemorrhagic Complications: The most prominent limitation of DAPT is the dose- and duration-dependent increase in bleeding risk. Prolonged DAPT (e.g., >90 days in stroke patients or >12 months in PCI patients) significantly elevates the risk of major, severe, and life-threatening hemorrhages without providing proportional ischemic benefits [1][2]. In TAVR patients, DAPT is strictly associated with higher bleeding rates compared to SAPT [7].
Drug Resistance and Interactions: Approximately one-third of stroke patients may experience recurrent events while on antiplatelet therapy due to aspirin or clopidogrel resistance [1]. Beyond genetic factors (CYP2C19 mutations), drug-drug interactions limit DAPT efficacy; for instance, concomitant use of NSAIDs (like ibuprofen) can offset aspirin's clinical benefit, and proton-pump inhibitors (PPIs) can inactivate the hepatic enzymes required for clopidogrel activation [1].
Perioperative Management: Managing DAPT during the perioperative period, such as before coronary artery bypass graft (CABG) surgery, presents a major challenge. Clinicians must balance the risk of surgical bleeding against the risk of stent thrombosis or ischemic events. Evidence suggests that withholding DAPT for more than 2 days prior to CABG reduces blood loss, but standardized protocols remain difficult to implement universally [8].
6. Future Perspectives
The future of DAPT lies in precision medicine and tailored de-escalation strategies designed to optimize the net clinical benefit:
Early Aspirin Withdrawal: There is a growing consensus supporting the de-escalation of DAPT to P2Y12 inhibitor monotherapy (e.g., ticagrelor or clopidogrel) after a short initial period (1 to 3 months) following PCI. This strategy has been shown to substantially reduce bleeding risks while maintaining robust protection against myocardial infarction and stent thrombosis [2][3][9].
Genotype-Guided Therapy: The integration of genetic testing for CYP2C19 loss-of-function alleles into routine clinical practice will allow for the personalized selection of P2Y12 inhibitors. Identifying poor metabolizers can direct the use of ticagrelor over clopidogrel, thereby overcoming genetic resistance and improving secondary stroke and cardiovascular prevention outcomes [1].
Individualized Risk Stratification: Future guidelines are expected to increasingly rely on individualized patient profiling, weighing absolute ischemic risks (e.g., acute coronary syndrome presentation, complex anatomy) against bleeding risks to determine the optimal intensity and duration of antithrombotic therapy [2][3].
